As 2019 ends, we would like to thank you for being part of the Eloquest Healthcare Blog! We hope you have found our posts both informative and impactful to your professional career.
We kicked 2019 off with new clinical evidence reviewing the qualitative and quantitative evidence supporting the use of Detachol® Liquid Adhesive for the reduction of CRBSI and MARSI. Detachol® Adhesive Remover is a nonirritating adhesive remover used to aid in the removal of dressings, tapes, and most sticky residue from the skin and other surfaces. Read more about the benefits of Detachol as they relate to improving outcomes, quality of care delivered and cost avoidance here.
One of our favorite blogs of the year featured a webinar presented by Gwen Borlaug, MPH, CIC, FAPIC, Infection Prevention Epidemiologist. Gwen led an in-depth discussion regarding interactions between Infection Preventionists and the surgical care team. We summarized the five key takeaways, which can be found here.
As the year progressed, we introduced new key pieces of clinical data. During the Association for Vascular Access (AVA) Annual Scientific Meeting in September of 2018, data from several quality improvement initiatives designed to increase dressing adhesion was presented. You can view some of those initiatives here.
Surgical site infection (SSI) is the most common and costly type of hospital‐acquired infection, occurring in an estimated 160,000 to 300,000 patients in the US each year. SSI increases morbidity and mortality risk, result in longer hospital stays and substantially increased cost of care. In one of our recent clinical study reviews, we looked at the challenge of methicillin‐resistant Staphylococcus aureus (MRSA) and the efficacy of CHG‐impregnated post‐op dressings in reducing bacterial bioburden and preventing SSI.
Rounding out our clinical data for the year, we dug into the vascular access dressing adherence and hospital-acquired Infections data presented at the Association for Vascular Access (AVA) Annual Scientific Meeting in October of 2019.
As we prepare to enter a new decade, Eloquest Healthcare wanted to leave a unique mark on 2019! This year we launched our new video series, “3 Questions With…”
Eloquest Healthcare’s “3 Questions With…” video series features some of the finest thought leaders in healthcare specialties such as Infection Prevention, Vascular Access, Surgical Care and more. These experts answer questions on the latest insights, evidence and current practices. Check out our inaugural video featuring Chellie DeVries, MPH, CIC, VA-BC.
As we look forward to 2020, we are excited to share and react to the changes and improvements taking place in the realms of hospital quality, patient safety, and HAI reduction! Make sure you subscribe to the Eloquest Healthcare Blog below so you don’t miss out on exciting new content in the year ahead!
For more information about Mastisol®, ReliaTect®, or Detachol®, please contact your sales consultant or Eloquest Healthcare®, Inc., call 1-877-433-7626 or visit www.eloquesthealthcare.com.
Minimizing infection risk is an essential part of optimizing “The Triple Aim” of the Affordable Care Act. Eloquest Healthcare is committed to providing solutions that can help you reduce the risk of conditions like a central line-associated bloodstream infection (CLABSI) and post-operative wound contamination.
- Ban KA, Minei JP, Laronga C, et al. American College of Surgeons and Surgical Infection Society: Surgical site infection guidelines, 2016 update. J Am Coll Surg. 2017;1:59‐74.